Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials

This pooled analysis evaluated the relationship of isavuconazole and voriconazole MICs of Aspergillus pathogens at baseline with all-cause mortality and clinical outcomes following treatment with either drug in the SECURE and VITAL trials. Isavuconazole and voriconazole may have had reduced efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Andes, David R., Ghannoum, Mahmoud A., Mukherjee, Pranab K., Kovanda, Laura L., Lu, Qiaoyang, Jones, Mark E., Santerre Henriksen, Anne, Lademacher, Christopher, Hope, William W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2018
Materias:
Susceptibility
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325202/
https://www.ncbi.nlm.nih.gov/pubmed/30373791
http://dx.doi.org/10.1128/AAC.01634-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325202/
https://www.ncbi.nlm.nih.gov/pubmed/30373791
http://dx.doi.org/10.1128/AAC.01634-18

Ejemplares similares